Results 31 to 40 of about 732,366 (171)

Percutaneous Transcatheter Valve-in-Valve Pulmonary and Tricuspid Replacement in Carcinoid Heart Disease

JACC: Case Reports, 2020
Surgical valve replacement is the most effective treatment for carcinoid heart disease; however, reoperation for prosthetic valve failure is burdened by high risk.
Suvitesh Luthra, MD, Carlo Olevano, MD, Trevor Richens, MD, Geoff M. Tsang, MD   +3 more
doaj   +1 more source

Sex Differences in Transcatheter Structural Heart Disease Interventions: How Much Do We Know?

Cardiovascular Innovations and Applications, 2023
The number of structural heart disease interventions has greatly increased in the past decade. Moreover, interest in the sex-specific outcomes of various cardiovascular conditions and procedures has increased.
Lina Ya’Qoub, Jelena Arnautovic, Nadeen N. Faza, Islam Y. Elgendy   +3 more
doaj   +1 more source

Transcatheter Valve Replacement in Severe Tricuspid Regurgitation [PDF]

BACKGROUND: Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.
Sharma, Rahul P, O\u27Neill, Brian P, Whisenant, Brian, Lim, D Scott, Hahn, Rebecca T, Mack, Michael J, Pislaru, Sorin, Smith, Robert, Sannino, Anna, Kodali, Susheel K, Garcia, Santiago, Lee, James, Thiele, Holger, Harb, Serge C, Thourani, Vinod H, Kipperman, Robert, Grayburn, Paul A, Eleid, Mackram, Kapadia, Samir, Fowler, Dale, Narang, Akhil, Szerlip, Molly, Lurz, Philipp, Makkar, Raj, Chadderdon, Scott, Yadav, Pradeep, Davidson, Charles J, Koulogiannis, Konstantinos, Haeffele, Christiane, Zahr, Firas, Sekaran, Nishant K, Leon, Martin B, Makar, Moody, Stewart-Dehner, Terri   +33 more
core   +3 more sources

Transcatheter Tricuspid Valve Replacement: Principles and Design

Frontiers in Cardiovascular Medicine, 2018
Tricuspid regurgitation (TR) may affect as much as 65–85% of the population with the prevalence of moderate-to-severe TR in the United States reported at greater than 1.6 million.
Ozan M. Demir, Ozan M. Demir, Damiano Regazzoli, Antonio Mangieri, Marco B. Ancona, Satoru Mitomo, Giora Weisz, Antonio Colombo, Azeem Latib, Azeem Latib   +9 more
doaj   +1 more source

First-in-Human Implantation of a New Transcatheter Tricuspid Valve Replacement System

JACC: Case Reports, 2023
Therapeutic options for patients with isolated severe to torrential tricuspid regurgitation have been limited. Because a surgical option is often not attractive, new catheter-based therapies are emerging.
Lars Sondergaard, MD, DMSc, Jacob Eifer Møller, MD, PhD, Ole De Backer, MD, PhD, Peter Hasse Møller-Sørensen, MD, PhD, Yanping Cheng, MD, Kasper Rossing, MD, DMSc, Morten Smerup, MD, Arshad Quadri, MD   +7 more
doaj   +1 more source

Transcatheter Tricuspid Valve Therapy: From Anatomy to Intervention

Frontiers in Cardiovascular Medicine, 2021
Nowadays, severe symptomatic tricuspid regurgitation (TR) affects millions of persons worldwide. However, the benefit of surgical correction of isolated secondary TR remains controversial because of the increased risk of periprocedural mortality and ...
Valeria Cammalleri, Myriam Carpenito, Maria Caterina Bono, Simona Mega, Gian Paolo Ussia, Francesco Grigioni   +5 more
doaj   +1 more source

Surgical outcomes of patients at prohibitive risk who are reconsidered for surgeryCentral MessagePerspective

JTCVS Open, 2023
Objectives: Transcatheter treatment of advanced mitral and tricuspid valve disease is largely limited to patients at prohibitive surgical risk, although many are not candidates for transcatheter treatment.
Catherine M. Wagner, MD, Megan L. Schultz, MD, Alexander A. Brescia, MD, MSc, Yoyo Wang, BS, Whitney Fu, MD, Robert B. Hawkins, MD, MSc, Matthew A. Romano, MD, Gorav Ailawadi, MD, MBA, Steven F. Bolling, MD   +8 more
doaj   +1 more source

Case report: Self-expanding transcatheter valve implantation (Acurate Neo 2) in a very small native aortic annulus

Frontiers in Cardiovascular Medicine, 2023
Transcatheter aortic valve replacement (TAVR) is a treatment of choice in patients with symptomatic severe aortic valve stenosis (AS) and intermediate-to-high surgical risk.
Massimo Medda, Francesco Casilli, Marta Bande, Maurizio Tespili, Francesco Donatelli   +4 more
doaj   +1 more source

Interdisciplinary three-step strategy to treat aortic stenosis and coronary artery disease in a patient with end-stage chronic obstructive pulmonary disease [PDF]

, 2012
Background: Valvular aortic stenosis is a common disease in the elderly, often in multimorbid patients. It is often associated with coronary artery disease and peripheral artery disease.
Michel, Sebastian, Schmitz, Christoph, Kaczmarek, Ingo, Sodian, Ralf, Wolf, Manuel, Bigdeli, Amir Khosrow, Beiras Fernández, Andrés   +6 more
core   +1 more source

Heterotopic Transcatheter Tricuspid Valve Replacement in Severe Tricuspid Regurgitation and Refractory Right Heart Failure

, 2022
Torrential tricuspid regurgitation may lead to heart failure and poor survival and quality of life. Heterotopic transcatheter tricuspid replacement is increasingly offered to patients unsuitable for direct valve repair or replacement.
Stazzoni, Laura, Marco De Carlo, De Carlo, Marco, Angelillis, Marco, Roberto Del Sorbo, Laura Stazzoni, Daniele Bozzoli, Bozzoli, Daniele, Giannini, Cristina, Anna Sonia Petronio, Del Sorbo, Roberto, Cristina Giannini, Spontoni, Paolo, Petronio, Anna Sonia, Paolo Spontoni, Marco Angelillis, Costa, Giulia, Giulia Costa   +17 more
core   +1 more source